2010
DOI: 10.1016/j.joca.2010.05.012
|View full text |Cite
|
Sign up to set email alerts
|

Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes

Abstract: Our results indicate that treatment with oral glucosamine sulfate in a rat OA model (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of cell p38 and JNK and increase of ERK expression.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
73
2
6

Year Published

2011
2011
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 82 publications
(86 citation statements)
references
References 46 publications
5
73
2
6
Order By: Relevance
“…The ACLT-induced rat model of OA was employed in this study because it is widely used and reproducible in a range of species including the rat [20,21,27,28] . This model mimics trauma-induced OA that develops following sports injuries in humans [27] .…”
Section: Discussionmentioning
confidence: 99%
“…The ACLT-induced rat model of OA was employed in this study because it is widely used and reproducible in a range of species including the rat [20,21,27,28] . This model mimics trauma-induced OA that develops following sports injuries in humans [27] .…”
Section: Discussionmentioning
confidence: 99%
“…Weight-bearing deficits were assessed as described in our previous publications [44,52]. Rats were placed on an incapacitance tester (Singa Technology Corporation, Taiwan) so that the hind paws were centered on the two force transducers, enabling the weight distribution between the rat's hind limbs to be measured.…”
Section: Weight-bearing Testmentioning
confidence: 99%
“…В то же время экзоген-ный ГКА не усиливал синтез ХС в культуре хондроцитов че-ловека. В экспериментах на животных лечение ГКА сущест-венно замедляло прогрессирование ОА [32]. Авторы также показали его способность модифицировать ноцицепцию у крыс.…”
Section: медленно действующие симптоматические препаратыunclassified